Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A12 | P48065 | 3/20 | 0.32 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.32 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20103415 | 0.78 | SLC6A12 (0.32) | SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL29294175 | 0.70 | DPP4 (0.35) | — | |
| SCHEMBL23033888 | 0.65 | — | — | |
| SCHEMBL29294176 | 0.65 | — | — | |
| SCHEMBL20103413 | 0.65 | HSD11B1 (0.32) | SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL15447883 | 0.64 | HTT (0.37) | — | |
| SCHEMBL22669311 | 0.60 | CES2 (0.39) | — | |
| SCHEMBL2796635 | 0.60 | CES2 (0.39) | — | |
| SCHEMBL19569728 | 0.60 | CES2 (0.39) | — | |
| SCHEMBL691392 | 0.59 | GABRR1 (0.46) | SLC6A12SLC6A11SLC6A13GABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230272111-A1 | Anti-MUC16 Antibodies, Antibody-Drug Conjugates, and Bispecific Antigen-Binding Molecules that Bind MUC16 and CD3, and Uses Thereof | REGENERON PHARMACEUTICALS, INC. | 2023-08-31 | — | — | US | disclosed |
| US-10941208-B2 | Anti-MUC16 antibodies | REGENERON PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20180118848-A1 | Anti-MUC16 Antibodies, Antibody-Drug Conjugates, and Bispecific Antigen-Binding Molecules that Bind MUC16 and CD3, and Uses Thereof | REGENERON PHARMACEUTICALS, INC. | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118848-A1 | Anti-MUC16 Antibodies, Antibody-Drug Conjugates, and Bispecific Antigen-Binding Molecules that Bind MUC16 and CD3, and Uses Thereof | MUC1, EPCAM, CD2 | SLC6A12 4092/4885SLC6A11 2717/4885SLC6A13 2112/4885 |
| US-10941208-B2 | Anti-MUC16 antibodies | MUC1, LGALS3BP, IGSF11 | SLC6A12 4676/4885SLC6A11 3975/4885SLC6A13 3379/4885 |
| US-20230272111-A1 | Anti-MUC16 Antibodies, Antibody-Drug Conjugates, and Bispecific Antigen-Binding Molecules that Bind MUC16 and CD3, and Uses Thereof | MUC1, EPCAM, CD2 | SLC6A12 4092/4885SLC6A11 2717/4885SLC6A13 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.